We need your input!
Kidney Cancer Canada is seeking input from patients and caregivers to support our Patient Evidence Submission to the pan-Canadian Oncology Drug Review (pCODR) with respect to INLTYA (axitinib). INLYTA (axitinib) is indicated for the treatment of patients with metastatic clear cell renal cell carcinoma (RCC) after progression on a prior systemic therapy with either a cytokine or the VEGFR-TKI, sunitinib.
The pan-Canadian Oncology Drug Review (pCODR) assesses cancer drugs and makes recommendations to the provinces and territories to guide their drug funding decisions. It is anticipated the pCODR will be assessing INLYTA (axitinib) later this summer. Your participation will help pCODR and provincial/territorial governments better understand the patient and caregiver perspectives concerning kidney cancer therapies.
To participate in the survey click here.
Our sincere thanks for your time and thoughtful input into the survey on behalf of Canadians affected by kidney cancer.